ProCE Banner Activity

CME

Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future

Text Module

In this module, 5 lung cancer experts discuss the rationale supporting the evaluation of TROP-2‒targeted antibody‒drug conjugates in NSCLC, review key efficacy and safety data including recommended supportive care strategies, and highlight important ongoing clinical trials.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 25, 2023

Expiration: July 24, 2024

No longer available for credit.

Share

Faculty

Hossein Borghaei

Hossein Borghaei, MS, DO

Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Melissa L. Johnson

Melissa L. Johnson, MD

Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Benjamin Levy

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with NSCLC.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of healthcare professionals treating patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the biologic rationale for targeting TROP-2 and features that differentiate the antibody–drug conjugates targeting TROP-2

  • Appraise current clinical trial data on TROP-2–targeting antibody–drug conjugates that may have future implications on the current treatment guidelines for NSCLC

  • Incorporate investigational TROP-2–targeting antibody–drug conjugates and clinical trial participation as part of therapeutic strategies for all eligible patients with NSCLC

  • Plan multidisciplinary supportive care plans to manage potential treatment-related symptoms from TROP-2‒targeted agents

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Hossein Borghaei, MS, DO

Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Hossein Borghaei, MS, DO: researcher: Amgen, Bristol-Myers Squibb, Lilly; consultant/advisor/speaker: Amgen, AstraZeneca, Axiom, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, BioNTech, Daiichi Sankyo, Da Volterra, EMD Serono, Genentech, Genmab, Guardant, iTEO, Janssen, Jazz, Lilly, Merck, Mirati, Natera, Novartis, Oncocyte, Pfizer, PharmaMar, Regeneron, Takeda; data and safety monitoring board: Incyte, Novartis, Takeda; stock options: Inspirna, Nucleai, Sonnetbio.

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Rebecca S. Heist, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, Claim Therapeutics, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron, Sanofi; researcher (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Erasca, Lilly, Mirati, Novartis, Turning Point.

Melissa L. Johnson, MD

Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Melissa L. Johnson, MD: research: AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Checkpoint Therapeutics, City of Hope National Medical Center, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics.

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Benjamin Levy, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Janssen, Mirati, Pfizer, Merck, Novartis.

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Stephen Liu, MD: consultant/advisor: AstraZeneca, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz, Merck, Merus, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher (paid to institution): Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; data and safety monitoring board: Candel Therapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 25, 2023, through July 24, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.